Antigen News and Research

RSS

FDA looks at nanotechnology for the detection of anthrax

The U.S. Food and Drug Administration has completed a "proof-of-concept" study of a test that quickly and accurately detects the presence of even the smallest amount of the deadly anthrax toxin.

17 Mar 2009

Selected men with low-risk prostate cancer have good clinical outcomes without immediate treatment

A multi-center study of prostate cancer patients appearing in today's Journal of Urology recommends that for some men diagnosed with low-risk prostate cancer, opting not to initially receive treatment can be safe if they are closely monitored.

16 Mar 2009

Dendritic cells ensure immune tolerance

One of the most important tasks of the immune system is to identify what is foreign and what is self. If this distinction fails, then the body's own structures will be attacked, the result of which could be an autoimmune disease such as diabetes mellitus type 1 or multiple sclerosis. The only way to protect against these afflictions is to destroy all immune factors that turn against the body's own tissue - in other words: immune tolerance.

16 Mar 2009

A blood test for Alzheimer's on the horizon

Researchers have revealed a direct relationship between two specific antibodies and the severity of Alzheimer's disease symptoms, raising hopes that a diagnostic blood test for the devastating disorder is within reach.

11 Mar 2009

Twin nanoparticle targets then zaps breast cancer cells

Breast cancer patients face many horrors, including those that arise when fighting the cancer itself.

11 Mar 2009

A vaccine for multiple sclerosis

Apitope Technology Ltd is a biopharmaceutical company that specialises in developing treatments for allergy and autoimmune diseases.

11 Mar 2009

Male lumpectomy - first line treatment for prostate cancer

The so-called "male lumpectomy" - a minimally invasive interventional radiology treatment for prostate cancer - is as effective as surgery in destroying diseased tumors and can be considered a first-line treatment for patients of all risk levels and particularly those who have failed radiation, according to studies released at the Society of Interventional Radiology's 34th Annual Scientific Meeting.

10 Mar 2009

Breakthrough improves effectiveness of tuberculosis vaccine

A breakthrough strategy to improve the effectiveness of the only tuberculosis vaccine approved for humans provided superior protection against the deadly disease in a pre-clinical test, report scientists at The University of Texas Health Science Center at Houston in Nature Medicine 's Advance Online Publication March 1.

8 Mar 2009

Bottom up assembly of cells into 3-D microtissues

Scientists at the U.S. Department of Energy's Lawrence Berkeley National Laboratory can now control how cells connect with one another in vitro and assemble themselves into three-dimensional, multicellular microtissues.

5 Mar 2009

Tuberculosis breakthrough could lead to stronger vaccine

3 Mar 2009

Antibody recognition of a highly conserved epitope across influenza viruses

The discovery of the molecule, an antibody known as CR6261, is good news for researchers who hope to design a flu vaccine that would give humans lifelong protection against a majority of influenza viruses.

26 Feb 2009

Liver transplant recipients with hepatitis B may need lifelong antiviral treatment

Patients who undergo liver transplantation for hepatitis B-related liver damage should receive lifelong antiviral treatment to keep the disease from coming back.

26 Feb 2009

Medivation announces new positive efficacy data from trial of MDV3100 in Castration-resistant prostate cancer

Medivation, Inc. has announced the presentation of new efficacy and safety data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (CRPC) patients.

25 Feb 2009

Xencor and CSL Limited establish antibody optimization collaboration

Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd. The collaboration will provide CSL with access to Xencor's XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies.

23 Feb 2009